Celgene has today confirmed that it will acquire Juno Therapeutics for $9 billion, and says the move will make it a leader in cell immunotherapy. The price is a significant premium on the $5.5 bn ...

Celgene has added another new indication for its blood cancer blockbuster Revlimid, with the FDA approving its use alongside Roche’s Rituxan for two additional forms of indolent non-Hodgkin’s ...

KELOWNA, B.C. - When veteran skip Brad Jacobs joined his new teammates last spring, one of their main goals was to make it to the last day of the Montana's Brier. Mission accomplished for the ...

After hours: March 11 at 7:39:19 PM EDT Loading Chart for J ...